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Abstract:
ST6Gal-I is a siayltransferase enzyme that catalyzes the addition of alpha-2,6
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sialic acids to galactose on N-linked glycoproteins post-translation. Previous research in
this lab has shown that this gene plays a role in both B cell and T cell responses to
LCMV infection. Specifically, ST6Gal-I deficient mice show reduced B cell, CD4 T cell,
and CD8 T cell responses on day 8 post-infection. Because of these reduced responses,
we examined the role of ST6Gal-I in viral clearance. After performing plaque assays to
detect viral titers, we determined that viral clearance in ST6Gal-I deficient mice was no
different from viral clearance in wild type mice on day 8. This leads us to conclude that
although ST6Gal-I plays a role in B cell and T cell responses to LCMV infection, it does
not affect viral clearance by day 8 post infection.

Introduction:
Previous research in this lab has shown that ST6Gal-I plays a role on immune
responses to infection. In figure 1 we show that ST6Gal-I knockout mice have reduced
LCMV specific antibody titers for both IgG and IgM at all time points shown, compared
to the wild type B6 mice.
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Figure 1. LCMV specific antibody titers at various days post infection, showing ST6Gal-I -f- mice always
have reduced response (Rajini Bheemreddy)

Research also shows that T cell responses are affected by ST6Gal-I. ST6Gal-I
knockout mice have reduced viral specific CD4 T cell responses on day 8 post infection,
as seen in Figure 2.
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Figure 2. Viral specific INFy producing CD4 T cells, showing reduced response in ST6Gal-I knockout
mice. (Rajini Bheemreddy)

2

The CD8 T cell response is also affected by ST6Gal-I. In figure 3 we show that
ST6Gal-I knockout mice have a reduced viral specific CD8 T cell response by day 8 post
infection. This is significant because the CD8 T cell response is the key population of
cells involved in LCMV to viral clearance. This data was highly influential in this
research project.
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Figure 3. Viral specific CD8 T cell responses, showing reduced response in ST6Gal-I knockout mice.
(Junwei Zeng and lenish Patel)

Because ST6Gal-I plays a role in both B cell and T cell responses, we decided to
look at its role in viral clearance. Previous research showed that by day 8, the virus was
cleared from the serum in both wild type and ST6Gal-I knockout mice. My project
involved looking at viral clearance in the tissues.

Objective:
ST6Gal-I deficient mice show reduced B cell, CD4 T cell, and CD8 T cell
responses. Considering this, we looked at the effects of ST6Gal-I on viral clearance.
Specifically, we studied how the loss of ST6Gal-I affects viral clearance in the tissues.
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Materials and Methods:
To examine viral clearance in tissues, we used a plaque assay method. This is a
2

technique used to determine viral titers. First, I maintained a VERO cell line for several
days. These cells are optimal for infection by LCMV. This is done prior to the plaque
assay. On the day before the assay begins, we count the cells and dilute them using
specific calculations. Next, we add cells to each well of several six-well plates. This step
is important because it allows an equal number of cells to be added per well, ensuring
that every well has the same chance of being infected by the virus, barring any cell
contamination.
On day one of the plaque assay, I homogenize a tissue suspected of containing
virus. The tissues we examined include the spleen, kidney, liver, and lung from both wild
type and knockout mice. All were from day 8 post-infection. I then add the tissue to a 96well plate and make serial dilutions. This step requires precision in pipetting technique
and maintaining sterilization. Then I transfer the diluted virus into the six-well plates.
The plates are incubated at 37°C for one hour and rocked every fifteen minutes. This
allows the virus to begin mixing with and infecting the cells. Finally, I add a 1: 1 mixture
of hot agarose and 2x 199 media to the wells. When it solidifies, the plates are incubated
at 37°C for three days. During this time, the cells are infected with virus and plaques
begin to form. A plaque is a clearing on the plate indicating cell death due to viral
infection. 3
On day four, another mixture of agarose and 2x199 is added to the wells.
However, during this step, 1% neutral-red dye is also added. Again, the solution solidifies
and the plates are incubated overnight. During this time, the viable cells take up the dye
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and stain red. The cells infected by the virus are killed and do not take up the dye. They
remain clear, and the plaques can be seen.
On the fifth day of the assay, the plaques on the plates are ready to be counted. I
count the plaques in each well, and then calculate the plaque forming units per ml for
each tissue used. This gives the viral titer. For each assay, a control virus with a known
viral titer was also used to ensure that the technique was performed correctly. For these
assays, LCMV -Armstrong was used as the control.
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Results:
Our results show that no virus was found in any tissue the wild type or the
knockout mice, as seen in Figure 4. Any virus in the tissues was below our limit of
detection, which was about 50pfu/ml (plaque forming unit per milliliter). These data
suggest that there is no difference in viral clearance between the wild type and the
ST6Gal-I knockout mice at day 8 post-infection.
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Figure 4. Viral titers in various tissues for wild type mice, ST6Gal-I knockout mice, control virus, showing
that viral clearance in the tissues is the same in the wild type and knockout mice.
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Conclusions:
The loss of ST6Gal-1 does not affect viral clearance at day 8 post-infection. Virus
(above the level of detection) was cleared from both the wild type and the ST6Gal-1
knockout mice.
There were some possible sources of error during these experiments. First, my
viral titers of the control plates were often lower than what they should have been.
Because the control plates still produced plaques, just at a lower rate than normal, it is
probable that there was error in my pipetting technique. For this reason, I can confidently
say that the control plates contained virus while the tissues did not, as far as my limit of
detection conveyed. (It is possible that because my technique might have been flawed,
my limit of detection was not as good as it should have been. It is possible that there were
traces of virus that I could not detect.) However, I could not confidently say the exact
viral titer for each tissue. Another important factor when considering this data is the unit
of measurement of the viral titer. In the future, should there be a need to compare viral
titers of these tissues, it would be better to measure in·pfu/ gram of tissue. This way,
tissues of different sizes can still be compared. It is also important to note that for the
control plates, straight LCMV -Armstrong was used instead of a tissue that we knew to be
infected. It would be beneficial to use infected tissue viral titers as a comparison, versus
the straight virus.
Future research concerning the role of ST6Gal-1 on viral clearance should be
conducted. Although ST6Gal-1 does not seem to affect viral clearance at day 8, it could
still playa role in clearing the virus at earlier time points. By comparing tissues from day
3 or day 4 post-infection from wild type and ST6Gal-1 knockout mice, a difference in
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viral clearance might be seen. This could lead to further knowledge of the role of
ST6Gal-I on immune responses to LCMV infection.
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response to LCMV infection
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• Sialyltransferase
• Catalyzes the addition of a2,6 sialic acids
linked to Gal~1-4GlcNAc
• ST6Gal-1 knockout mice show reduced B
cell and T cell responses

Antibody titers at various time points
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• Enveloped RNA virus
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Plaque Assay
Question:
How does the loss of ST6Gal-1
affect viral clearance?

• Technique used to determine viral titers
• Infect VERO cells with LCMV
• Cells take up virus ~ Virus replicates ~ causes
cell death
• Stain cells (only viable
cells take up dye)
• Count plaques
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Viral Titers

Determining Viral Titers:
Plaque Count x 5 x 10x = pfu/mL
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Conclusions:
• In ST6Gal-1 knockout mice, although there
is a reduced B cell and T cell response,
the virus was cleared at day 8.
• Need to look at earlier time points to
observe differences
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